REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.

The safety profile of Dupixent in adolescents with moderate-to-severe asthma contributed to the FDA's decision.

Eleven months after sustaining a rejection from the FDA for Dupixent to treat chronic spontaneous urticaria (CSU), Sanofi and ...

Regeneron (REGN) and Sanofi (SNY) announce successful Phase 3 outcome for Dupixent in bullous pemphigoid, but not in chronic ...

Sanofi and Regeneron’s blockbuster drug Dupixent successfully treated patients with an inflammatory skin disease in a ...

Sanofi and Regeneron’s superstar anti-inflammatory biologic Dupixent is on a roll. | It was a busy day for Sanofi and ...

Regeneron and Sanofi's Dupixent achieves positive Phase 3 results for chronic spontaneous urticaria, meeting key endpoints.

Regeneron Pharmaceuticals, Inc. REGN announced that the FDA has approved blockbuster drug Dupixent (dupilumab) for the indication of chronic rhinosinusitis with nasal polyps (CRSwNP) for a broader ...

Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNPCurrent treatment ...

Drug makers Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Wednesday that ADEPT study of Dupixent (dupilumab) in ...